NO992186L - System med forsinket avlevering for syresensitive medikamenter - Google Patents

System med forsinket avlevering for syresensitive medikamenter

Info

Publication number
NO992186L
NO992186L NO992186A NO992186A NO992186L NO 992186 L NO992186 L NO 992186L NO 992186 A NO992186 A NO 992186A NO 992186 A NO992186 A NO 992186A NO 992186 L NO992186 L NO 992186L
Authority
NO
Norway
Prior art keywords
delivery system
acid
barrier
omeprazole
pulsatile
Prior art date
Application number
NO992186A
Other languages
English (en)
Other versions
NO992186D0 (no
Inventor
Vinay K Sharma
Original Assignee
Sharmatek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sharmatek Inc filed Critical Sharmatek Inc
Publication of NO992186D0 publication Critical patent/NO992186D0/no
Publication of NO992186L publication Critical patent/NO992186L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
NO992186A 1996-11-06 1999-05-05 System med forsinket avlevering for syresensitive medikamenter NO992186L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74098196A 1996-11-06 1996-11-06
PCT/US1997/020851 WO1998019668A1 (en) 1996-11-06 1997-11-05 Delayed delivery system for acid-sensitive drugs

Publications (2)

Publication Number Publication Date
NO992186D0 NO992186D0 (no) 1999-05-05
NO992186L true NO992186L (no) 1999-05-05

Family

ID=24978866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992186A NO992186L (no) 1996-11-06 1999-05-05 System med forsinket avlevering for syresensitive medikamenter

Country Status (7)

Country Link
EP (1) EP0941074B1 (no)
AT (1) ATE271379T1 (no)
AU (1) AU5179898A (no)
DE (1) DE69729950T2 (no)
NO (1) NO992186L (no)
WO (1) WO1998019668A1 (no)
ZA (1) ZA979937B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2244167T3 (es) * 1999-12-16 2005-12-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Nuevas preparaciones farmaceuticas multiunitarias estables que contienen bencimidazoles sustituidos.
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ES2663873T3 (es) * 2001-10-29 2018-04-17 Massachusetts Institute Of Technology Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
CA2518780C (en) * 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
WO2005051362A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
CA2570796A1 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
ES2336719T3 (es) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas.
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CA2661613C (en) * 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.

Also Published As

Publication number Publication date
EP0941074B1 (en) 2004-07-21
NO992186D0 (no) 1999-05-05
DE69729950D1 (de) 2004-08-26
EP0941074A1 (en) 1999-09-15
AU5179898A (en) 1998-05-29
ATE271379T1 (de) 2004-08-15
DE69729950T2 (de) 2005-07-28
ZA979937B (en) 1999-05-18
WO1998019668A1 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
NO992186L (no) System med forsinket avlevering for syresensitive medikamenter
AU1488295A (en) Pharmaceutical composition
DE60021604D1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
NO982302L (no) Farmas°ytisk sammensetning
NZ237516A (en) Device for drug delivery to intestinal tract comprising a core of active ingredient together with osmotically activated expulsion agent and an outer coating containing a hydrophobic material to assist in delaying release
MX9500885A (es) Preparacion farmaceutica para administracion oral.
NO20003640L (no) Ny doseringsform
RU99126869A (ru) Фармацевтический препарат омепразола
IT1246382B (it) Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
DK0754452T3 (da) Farmaceutisk præparat i form af en overtrukket kapsel, der frigives i den nedre del af fordøjelsessystemet
US5824341A (en) Composition providing selective release of an active ingredient
MXPA05001243A (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion.
EP1217992A1 (en) Coated solid dosage forms
KR20220113697A (ko) 알칼리제 및 장용성 코팅층을 포함하는 투여 형태
AU736357B2 (en) Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient
WO2001078681A1 (fr) Systeme d'administration de medicament empechant l'interaction pharmacocinetique entre les medicaments et procede correspondant
AU2009247712B2 (en) Compositions and methods for inhibiting gastric acid secretion
US20060043207A1 (en) Apparatus, kit and related methods for administering substances
US20220202721A1 (en) Articles and methods for administration of therapeutic agents
US6074669A (en) Controlled drug delivery system for diltiazem
JPH06256166A (ja) 薬物放出制御製剤
WO2020130450A1 (ko) 잘토프로펜 함유 서방성 의약 조성물
SA99190969B1 (ar) صورة جرعة صيدلانية ذات اطلاق نبضي pulsed relrase dosage form تؤخذ عن طريق الفم
TH57760B (th) การลำเลียงยาสู่ลำไส้เล็กและลำไส้ใหญ่โดยใช้แคปซูลชนิด hpmc
KR20220113698A (ko) 질환을 치료 또는 예방하는데 사용하기 위한 투여 형태

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application